The Manufacturers Life Insurance Company Acquires 161,940 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• The Manufacturers Life Insurance Company increased its stake in Jazz Pharmaceuticals PLC by 45.8%, now holding approximately 0.84% of the company valued at nearly $64 million.
• Jazz Pharmaceuticals reported a quarterly loss of ($8.25) EPS, missing analysts' expectations, while revenue remained steady at $1.05 billion compared to estimates.
• Recent analyst ratings have been mixed, with Royal Bank of Canada raising their target price to $151.00 while Robert W. Baird lowered it to $155.00, reflecting differing outlooks on the company's performance.

The Manufacturers Life Insurance Company lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 45.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 515,407 shares of the specialty pharmaceutical company's stock after acquiring an additional 161,940 shares during the quarter. The Manufacturers Life Insurance Company owned 0.84% of Jazz Pharmaceuticals worth $63,988,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Versant Capital Management Inc lifted its position in shares of Jazz Pharmaceuticals by 9.4% during the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock worth $131,000 after purchasing an additional 91 shares during the last quarter. Kendall Capital Management boosted its position in Jazz Pharmaceuticals by 1.2% during the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after purchasing an additional 95 shares during the period. Louisiana State Employees Retirement System lifted its position in Jazz Pharmaceuticals by 0.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock valued at $2,098,000 after purchasing an additional 100 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its position in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock valued at $1,046,000 after purchasing an additional 110 shares during the last quarter. Finally, Cardinal Capital Management lifted its position in Jazz Pharmaceuticals by 0.9% in the 1st quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company's stock valued at $1,645,000 after purchasing an additional 114 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on JAZZ. The Goldman Sachs Group lifted their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research report on Friday, August 29th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Morgan Stanley increased their target price on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price for the company. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $178.67.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $3.69 on Thursday, hitting $128.04. 487,447 shares of the stock were exchanged, compared to its average volume of 945,175. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The firm has a market capitalization of $7.77 billion, a PE ratio of -19.02, a P/E/G ratio of 8.04 and a beta of 0.24. The firm's 50 day moving average is $115.82 and its two-hundred day moving average is $117.12.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.